EXPLORE MORE CATEGORIES
- Home
- ยป
- Our Products
- »
- Anti Cancer Injection
Anti Cancer Injection
Our product range includes a wide range of leuprolide injection (bdsure 11.25mg injection), leuprolide injection (bdsure 22.5mg injection), trasturel 440mg injection, injectafer 750mg / 15ml injection, trastuzumab emtansine (ujvira) and trumab 440 mg injection.
Leuprolide Injection (Bdsure 11.25mg Injection)
Product Price: Rs 11,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 11.25 mg |
| Country of Origin | Made in India |
| Brand | Bdsure |
| Manufacturer | BDR Pharmaceuticals Internationals Pvt. Ltd |
| Packaging Size | 1 Injection in 1 vial |
| Form | Injection |
| Treatment | Treatment of Prostate cancer |
Yes! I am InterestedRequest A Callback
Leuprolide Injection (Bdsure 22.5mg Injection)
Product Price: Rs 14,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 22.5 mg |
| Packaging Type | Vial |
| Brand | Bdsure |
| Manufacturer | BDR Pharmaceuticals Internationals Pvt. Ltd |
| Packaging Size | 1 Injection in 1 Vial |
| Treatment | Treatment of Prostate cancer |
Yes! I am InterestedRequest A Callback
Trasturel 440mg injection
Product Price: Rs 39,000 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 440 mg |
| Packaging Type | Vial |
| Brand Name | Trasturel |
| Manufactured By | Reliance Life Sciences |
| Dose | 20 ml |
Trastuzumab is primarily indicated for:
- Treatment of HER2-positive breast cancer, including:
- Early-stage breast cancer (in conjunction with chemotherapy)
- Metastatic breast cancer
- Metastatic gastric or gastroesophageal junction adenocarcinoma that overexpresses the HER2 protein.
Trastuzumab is a monoclonal antibody that specifically binds to the HER2/neu receptor. By binding to this receptor, it inhibits the proliferation of cancer cells that overexpress HER2 and mediates antibody-dependent cellular cytotoxicity (ADCC), leading to cell death.
Dosage and Administration:- Dosage: The standard dose for metastatic breast cancer is 440 mg administered as an intravenous infusion every three weeks after an initial loading dose (typically 8 mg/kg).
- Administration: Administer via intravenous infusion. Infusion rates may vary; monitor the patient for infusion-related reactions.
- Hypersensitivity to trastuzumab or any component of the formulation.
- History of serious infusion reactions.
- Cardiac Effects: Monitor cardiac function before and during treatment, as trastuzumab can cause heart failure, particularly in patients with pre-existing cardiac conditions.
- Infusion Reactions: Patients may experience infusion-related reactions, which can include fever, chills, and hypotension. Monitor closely during the first infusion.
- Pregnancy and Nursing: Avoid use during pregnancy; it may cause fetal harm. Not recommended for breastfeeding.
Common Side Effects:
- Fever
- Nausea
- Fatigue
- Diarrhea
- Headache
Serious Side Effects:
- Heart failure
- Severe allergic reactions
- Infusion-related reactions (e.g., chills, hypotension)
Trastuzumab may interact with other medications affecting cardiac function or other cancer treatments. Patients should inform their healthcare provider about all medications and supplements they are taking.
Storage:- Store in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
- Advise patients to report any signs of heart problems, such as shortness of breath or swelling.
- Discuss the potential for infusion reactions and the importance of monitoring during the infusion.
- Inform patients about the potential side effects and the need for regular follow-up appointments.
Trastuzumab is an effective treatment for HER2-positive breast cancer and certain gastric cancers, requiring careful monitoring for cardiac side effects and infusion reactions. Always consult a healthcare professional for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Injectafer 750mg / 15ml injection
Product Price: Rs 850 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 750 mg |
| Brand | Injectafer |
| Total Strength | 50mg/ml |
| Packaging Type | Vial |
| Packaging Size | 750 mg / 15 ml |
| Manufacturer | Vifor (International) Inc. |
| Brand Name | Injectafer |
| Treatment | Lack of iron sickliness |
Injectafer is indicated for the treatment of:
- Iron deficiency anemia in adults, particularly in patients who:
- Have chronic kidney disease (CKD)
- Are unable to tolerate oral iron supplements
- Have had inadequate response to oral iron therapy
Ferric carboxymaltose is a parenteral iron replacement product. It provides iron for erythropoiesis (red blood cell production) by delivering ferric iron in a stable form that is readily available for incorporation into hemoglobin and other iron-containing proteins.
Dosage and Administration:- Dosage: The typical dose is 750 mg (15 ml) administered as an intravenous infusion. In cases of more severe iron deficiency, a second dose may be administered after at least 7 days, with the total cumulative dose based on the patient's weight and hemoglobin levels.
- Administration: Injectafer can be administered as a slow intravenous injection or as an infusion over a period of 15 minutes. Ensure proper technique to avoid complications.
- Hypersensitivity to ferric carboxymaltose or any component of the formulation.
- Non-iron deficiency anemia (e.g., anemia of chronic disease).
- Active or recent history of serious hypersensitivity reactions to parenteral iron products.
- Hypersensitivity Reactions: Monitor for signs of anaphylaxis and other allergic reactions during and after administration.
- Iron Overload: Avoid use in patients with conditions that increase iron stores (e.g., hemochromatosis, hemosiderosis).
- Monitoring: Regular monitoring of iron levels and hemoglobin is recommended during treatment.
Common Side Effects:
- Nausea
- Vomiting
- Headache
- Dizziness
- Injection site reactions (pain, redness, swelling)
Serious Side Effects:
- Hypersensitivity reactions (including anaphylaxis)
- Iron overload
- Hypotension
Injectafer may interact with other iron supplements or medications that can affect iron metabolism. Patients should inform their healthcare provider about all medications they are taking.
Storage:- Store at room temperature (20°C to 25°C or 68°F to 77°F). Protect from light and do not freeze.
- Advise patients to report any signs of allergic reactions or severe side effects.
- Discuss the importance of monitoring iron levels and following up with healthcare appointments.
- Inform patients about possible side effects, including gastrointestinal symptoms.
Injectafer is an effective treatment for iron deficiency anemia, especially in patients who cannot tolerate oral iron. Careful monitoring for side effects and regular follow-up is essential. Always consult a healthcare professional for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Trastuzumab Emtansine (Ujvira)
Product Price: Rs 33,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100mg |
| Packaging Type | Vial |
| Brand Name | Ujvira |
| Manufactured By | Zydus ingenia |
| Shelf Life | 24 Months |
| Dose | 160 mg |
Trastuzumab emtansine, marketed as UJVIRA, is an antibody-drug conjugate used in the treatment of HER2-positive breast cancer. It combines trastuzumab, a targeted therapy that binds to the HER2 receptor, with emtansine, a cytotoxic agent, enhancing the drug's ability to deliver chemotherapy directly to cancer cells.
IndicationsTrastuzumab emtansine is indicated for:
- HER2-Positive Breast Cancer: Used in patients who have previously received trastuzumab and a taxane, either in the neoadjuvant or adjuvant setting, or for metastatic breast cancer after prior treatment.
Trastuzumab emtansine targets HER2-positive cancer cells through trastuzumab, leading to internalization of the drug. Once inside the cell, emtansine disrupts microtubule function, causing cell cycle arrest and apoptosis. This dual mechanism effectively reduces tumor growth and metastasis.
Dosage and Administration- Standard Dosage: The recommended dose of Trastuzumab emtansine (UJVIRA) is typically 3.6 mg/kg administered intravenously every three weeks.
- Administration: It should be given by a healthcare professional. Infusion reactions may occur, so monitoring during and after the infusion is essential.
Trastuzumab emtansine is contraindicated in:
- Hypersensitivity: Patients with known allergies to trastuzumab, emtansine, or any components of the formulation.
- Pregnancy: Should not be used during pregnancy due to potential fetal harm.
- Cardiac Toxicity: Monitor patients for signs of heart failure, especially those with pre-existing heart conditions. Regular assessment of left ventricular function is recommended.
- Infusion Reactions: Patients may experience infusion-related reactions. Pre-medication may be considered for those with a history of such reactions.
- Hepatotoxicity: Liver function should be monitored, as hepatotoxicity can occur.
Common side effects may include:
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Headache
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiac events (e.g., heart failure)
- Hepatotoxicity
- Thrombocytopenia (low platelet count)
Trastuzumab emtansine may interact with other medications, particularly those affecting liver enzymes. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Trastuzumab emtansine (UJVIRA) in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep out of reach of children.
Patient Counseling Information- Advise patients to report any signs of heart problems, unusual bleeding, or severe allergic reactions.
- Discuss potential side effects and emphasize the importance of adhering to the treatment regimen.
- Encourage regular follow-up appointments for monitoring health and managing side effects.
Trastuzumab emtansine (UJVIRA) is a crucial therapy for HER2-positive breast cancer, offering targeted treatment with a dual-action approach. Close monitoring and open communication with healthcare providers are vital for managing side effects and optimizing treatment outcomes.
Yes! I am InterestedRequest A Callback
Trumab 440 Mg Injection
Product Price: Rs 43,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 440 mg |
| Physical Form | Lyophilized Powder |
| Drug Type | Standard Trastuzumab |
| Brand Name | Trumab |
| Manufactured By | Glenmark Pharmaceuticals Ltd |
| Packaging Type | Vial |
| Side Effect | Anemia,Decreased blood cells,Insomnia,Stomatitis |
| Directions for Use | Breast cancer,Stomach cancer |
Trumab, containing Trastuzumab, is an injectable monoclonal antibody used primarily for the treatment of HER2-positive breast cancer and gastric cancer. It targets the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells.
IndicationsTrumab is indicated for:
- HER2-Positive Breast Cancer: Used in early-stage and metastatic settings, often in combination with chemotherapy.
- HER2-Positive Gastric Cancer: Used for metastatic cases in combination with other therapies.
Trumab works by binding to the HER2 receptor on cancer cells, blocking its ability to promote cell division and survival. This binding triggers immune-mediated responses that can help destroy the cancer cells, reducing tumor growth and preventing metastasis.
Dosage and Administration- Standard Dosage: The recommended dose of Trumab 440 mg is typically 8 mg/kg as a loading dose, followed by 6 mg/kg every three weeks.
- Administration: Trumab is administered via intravenous infusion. The initial infusion is given slowly, with monitoring for infusion-related reactions.
Trumab is contraindicated in:
- Hypersensitivity: Known allergy to trastuzumab or any component of the formulation.
- Pregnancy and Lactation: Should be avoided during pregnancy due to potential harm to the fetus.
- Cardiac Function: Monitor patients for signs of heart failure or reduced left ventricular function, particularly in those with pre-existing heart conditions.
- Infusion Reactions: Infusion-related reactions may occur; patients should be monitored during and after administration.
- Pulmonary Issues: Assess for interstitial lung disease or pneumonitis, as these conditions can occur with trastuzumab.
Common side effects may include:
- Fatigue
- Nausea and vomiting
- Diarrhea
- Headache
- Rash
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiac dysfunction (e.g., heart failure)
- Lung problems (e.g., interstitial lung disease)
- Infusion-related reactions
Trumab may interact with other medications, especially those affecting heart function or liver enzymes. Patients should inform their healthcare provider of all medications being taken, including over-the-counter drugs and supplements.
Storage InstructionsStore Trumab 440 mg Injection in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep out of reach of children.
Patient Counseling Information- Advise patients to report any symptoms of heart problems, allergic reactions, or respiratory issues.
- Discuss potential side effects and the importance of adhering to the prescribed treatment regimen.
- Encourage regular follow-up appointments to monitor treatment effectiveness and manage any adverse effects.
Trumab 440 mg Injection is an essential therapy for HER2-positive breast and gastric cancers, utilizing targeted treatment to improve patient outcomes. Close monitoring and effective communication with healthcare providers are crucial for managing side effects and optimizing treatment success.
Yes! I am InterestedRequest A Callback
Rituximab Injection 500 Mg (RituxuRel 500 Mg)
Product Price: Rs 9,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 500 mg |
| Packaging Type | Vial |
| Packaging Size | 50 ml |
| Brand | RituxiRel |
| Manufacturer | Reliance Life Sciences |
| Storage | Store in a refrigerator (2 - 8 DegreeC). Do not freeze. |
Rituximab, marketed as RituxuRel 500 mg, is a monoclonal antibody used primarily in the treatment of certain types of cancers and autoimmune diseases. It targets the CD20 protein found on the surface of B cells, leading to the destruction of these cells.
IndicationsRituximab is indicated for:
- Non-Hodgkin Lymphoma (NHL): Used in various types, including diffuse large B-cell lymphoma.
- Chronic Lymphocytic Leukemia (CLL): Often used in combination with chemotherapy.
- Rheumatoid Arthritis: Used in combination with methotrexate for adults who have had an inadequate response to other treatments.
- Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Used for severe cases.
Rituximab works by binding to the CD20 antigen on B cells, leading to their destruction through several mechanisms, including:
- Complement-dependent cytotoxicity (CDC)
- Antibody-dependent cellular cytotoxicity (ADCC)
- Induction of apoptosis (programmed cell death)
This dual action reduces the number of B cells, which are involved in both cancer progression and autoimmune responses.
Dosage and Administration- Standard Dosage: The dosing of RituxuRel 500 mg varies depending on the condition being treated. For NHL and CLL, typical doses are 375 mg/m² on Day 1 of each treatment cycle.
- Administration: Rituximab is administered intravenously. Initial infusions should be given slowly to monitor for infusion reactions.
Rituximab is contraindicated in:
- Hypersensitivity: Known allergy to rituximab or any components of the formulation.
- Severe Active Infections: Patients with serious infections should not receive treatment until resolved.
- Infusion Reactions: Patients may experience infusion-related reactions; monitoring during infusion is essential.
- Infections: Increased risk of infections, including reactivation of hepatitis B. Screen patients prior to starting treatment.
- Cardiac Events: Patients with a history of heart problems should be monitored closely during treatment.
Common side effects may include:
- Fever and chills
- Fatigue
- Nausea
- Headache
- Rash
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Infusion-related reactions (e.g., hypotension, bronchospasm)
- Infections (including serious infections)
- Tumor lysis syndrome (TLS)
Rituximab may interact with other medications, especially those that suppress the immune system. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Rituximab Injection 500 mg (RituxuRel) in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep out of reach of children.
Patient Counseling Information- Advise patients to report any signs of allergic reactions, infections, or unusual symptoms.
- Discuss the potential side effects and the importance of adhering to the treatment schedule.
- Encourage regular follow-up appointments for monitoring treatment response and managing side effects.
Rituximab Injection 500 mg is a vital therapy for treating various B-cell malignancies and autoimmune disorders. Close monitoring and effective communication with healthcare providers are essential for managing side effects and optimizing treatment outcomes.
Yes! I am InterestedRequest A Callback
Rituximab 500 mg/50 ml (Maball 500)
Product Price: Rs 8,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 500 mg |
| Packaging Type | Vial |
| Packaging Size | 50 ml |
| Brand | Maball |
| Manufacturer | Hetero Drugs Ltd |
| Storage | Store in a refrigerator (2 - 8 DegreeC). Do not freeze. |
Rituximab, marketed as Maball 500, is a monoclonal antibody primarily used to treat certain types of cancers and autoimmune diseases. It specifically targets the CD20 antigen found on the surface of B cells, leading to the depletion of these cells.
IndicationsRituximab is indicated for:
- Non-Hodgkin Lymphoma (NHL): Effective in various subtypes, including diffuse large B-cell lymphoma.
- Chronic Lymphocytic Leukemia (CLL): Commonly used in combination with chemotherapy.
- Rheumatoid Arthritis: Used with methotrexate in adults who have not responded adequately to other treatments.
- Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Treatment for severe cases.
Rituximab binds to the CD20 protein on B cells, triggering their destruction through:
- Complement-Dependent Cytotoxicity (CDC): Activates the complement system to lyse the target cells.
- Antibody-Dependent Cellular Cytotoxicity (ADCC): Engages immune effector cells to kill the B cells.
- Induction of Apoptosis: Promotes programmed cell death in targeted cells.
- Standard Dosage: The usual dose for Maball 500 is 375 mg/m² administered as an intravenous infusion, typically on Day 1 of each treatment cycle.
- Administration: Rituximab should be given by a healthcare professional. Infusion rates may need to be adjusted based on patient tolerance.
Rituximab is contraindicated in:
- Hypersensitivity: Known allergy to rituximab or any of its components.
- Severe Active Infections: Patients should be free of serious infections before starting treatment.
- Infusion Reactions: Patients may experience reactions during infusion; monitoring is critical, especially during the first infusion.
- Infection Risk: Increased susceptibility to infections, including hepatitis B reactivation. Screening is recommended prior to treatment.
- Cardiovascular Events: Patients with heart issues should be closely monitored during treatment.
Common side effects may include:
- Fever and chills
- Fatigue
- Nausea
- Headache
- Rash
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Infusion-related reactions (e.g., hypotension, bronchospasm)
- Serious infections
- Tumor lysis syndrome (TLS)
Rituximab may interact with other medications, particularly those that suppress the immune system. It’s important for patients to inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Rituximab 500 mg/50 mL (Maball 500) in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze and protect from light. Keep out of reach of children.
Patient Counseling Information- Advise patients to report any signs of allergic reactions, infections, or unusual symptoms.
- Discuss the potential side effects and emphasize adherence to the treatment schedule.
- Encourage regular follow-up appointments for monitoring treatment efficacy and managing any side effects.
Rituximab 500 mg/50 mL (Maball 500) is an essential therapy for treating various B-cell malignancies and autoimmune conditions. Close monitoring and effective communication with healthcare providers are crucial for managing side effects and ensuring optimal treatment outcomes.
Yes! I am InterestedRequest A Callback
Trastuzumab Injection (Herti 150mg)
Product Price: Rs 10,500 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 150 mg |
| Packaging Type | Vial |
| Brand Name | Herti |
| Manufactured By | Hetero Healthcare Limited |
| Storage | Store in a refrigerator (2 - 8 DegreeC). Do not freeze. |
Trastuzumab, marketed as Herti 150 mg, is a monoclonal antibody used primarily for the treatment of HER2-positive breast cancer and gastric cancer. It specifically targets the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells.
IndicationsTrastuzumab is indicated for:
- HER2-Positive Breast Cancer: Used in both early-stage and metastatic settings, often in combination with chemotherapy.
- HER2-Positive Gastric Cancer: Indicated for patients with advanced disease in combination with other therapies.
Trastuzumab binds to the HER2 receptor on the surface of cancer cells, blocking its activation and signaling pathways that promote cell proliferation and survival. This binding also triggers immune-mediated responses, leading to the destruction of cancer cells.
Dosage and Administration- Standard Dosage: The recommended dose of Herti 150 mg is typically 4 mg/kg as a loading dose, followed by 2 mg/kg administered weekly or 6 mg/kg every three weeks, depending on the treatment plan.
- Administration: Trastuzumab is given via intravenous infusion. The initial infusion should be administered slowly, with careful monitoring for infusion reactions.
Trastuzumab is contraindicated in:
- Hypersensitivity: Known allergy to trastuzumab or any component of the formulation.
- Pregnancy and Lactation: Should be avoided during pregnancy due to potential harm to the fetus.
- Cardiac Function: Monitor patients for signs of heart failure, especially those with pre-existing heart conditions. Regular assessment of left ventricular function is recommended.
- Infusion Reactions: Patients may experience infusion-related reactions; monitoring during and after infusion is essential.
- Pulmonary Issues: Assess for potential interstitial lung disease or pneumonitis.
Common side effects may include:
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Headache
- Rash
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiac dysfunction (e.g., heart failure)
- Lung problems (e.g., interstitial lung disease)
- Infusion-related reactions
Trastuzumab may interact with other medications, particularly those that affect heart function or have immunosuppressive effects. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Trastuzumab Injection (Herti 150 mg) in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep out of reach of children.
Patient Counseling Information- Advise patients to report any symptoms of heart problems, allergic reactions, or respiratory issues.
- Discuss potential side effects and emphasize the importance of adhering to the prescribed treatment regimen.
- Encourage regular follow-up appointments for monitoring treatment effectiveness and managing side effects.
Trastuzumab Injection (Herti 150 mg) is a crucial therapy for HER2-positive breast and gastric cancers, providing targeted treatment that can significantly improve patient outcomes. Close monitoring and effective communication with healthcare providers are essential for managing side effects and optimizing treatment success.
Yes! I am InterestedRequest A Callback
Trastuzumab Injection (Trasturel 150mg Injection)
Product Price: Rs 18,500 / PackGet Best Price
Product Brochure
Product Details:
| Strength | 150 mg |
| Packaging Type | Vial |
| Brand Name | Trasturel |
| Manufactured By | Reliance Life Sciences |
| Pack Size | 1 Injection in 1 Vial |
| Treatment | Breast cancer |
Trastuzumab, marketed as Trasturel 150 mg, is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It is primarily used in the treatment of HER2-positive breast cancer and gastric cancer, known for its effectiveness in inhibiting tumor growth.
IndicationsTrastuzumab is indicated for:
- HER2-Positive Breast Cancer: Used in both early-stage and metastatic forms, often combined with chemotherapy.
- HER2-Positive Gastric Cancer: Administered alongside other therapies for advanced gastric cancer.
Trastuzumab binds specifically to the HER2 receptor, inhibiting its signaling pathways that promote cancer cell growth and proliferation. It also enhances immune responses against tumor cells, leading to their destruction.
Dosage and Administration- Standard Dosage: The initial dose of Trasturel 150 mg is usually 4 mg/kg as a loading dose, followed by 2 mg/kg weekly or 6 mg/kg every three weeks, depending on the treatment protocol.
- Administration: Given intravenously, the first infusion should be administered slowly, with monitoring for infusion-related reactions.
Trastuzumab is contraindicated in:
- Hypersensitivity: Known allergy to trastuzumab or any components of the formulation.
- Pregnancy and Lactation: Should not be used during pregnancy due to potential risks to the fetus.
- Cardiac Monitoring: Patients should be monitored for signs of heart failure, especially those with pre-existing cardiac issues. Regular assessment of left ventricular function is recommended.
- Infusion Reactions: Patients may experience reactions during infusion; monitoring during and after administration is essential.
- Pulmonary Risks: Assess for potential interstitial lung disease or pneumonitis.
Common side effects may include:
- Fatigue
- Nausea
- Diarrhea
- Rash
- Headache
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiac dysfunction (e.g., heart failure)
- Lung problems (e.g., interstitial lung disease)
- Infusion-related reactions
Trastuzumab may interact with other medications, particularly those affecting cardiac function. Patients should inform healthcare providers about all medications they are taking.
Storage InstructionsStore Trastuzumab Injection (Trasturel 150 mg) in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep out of reach of children.
Patient Counseling Information- Advise patients to report any symptoms of heart problems, allergic reactions, or respiratory issues.
- Emphasize the importance of adhering to the treatment schedule and attending regular follow-up appointments for monitoring health.
- Inform patients about potential side effects and when to seek medical attention.
Trastuzumab Injection (Trasturel 150 mg) is a critical treatment for HER2-positive breast and gastric cancers, providing targeted therapy that can significantly improve patient outcomes. Close monitoring and effective communication with healthcare providers are essential for managing potential side effects and ensuring optimal treatment success.
Yes! I am InterestedRequest A Callback
Ferium 1k Injection Ferric Carboxymaltose 1g/20ml Injection
Product Price: Rs 4,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 1000 mg |
| Brand | Ferium |
| Packaging Type | Vial |
| Composition | Ferric Carboxymaltose 1g/20ml Injection |
| Packaging size | 1g / 20 ml |
| Brand Name | Ferium |
| Manufacturer | Emcure Pharmaceuticals Ltd |
Ferium 1k Injection is an iron supplement used to treat or prevent iron deficiency anemia, particularly in patients who may not be able to absorb iron from oral supplements effectively. It provides a direct source of iron to help restore adequate levels in the body.
IndicationsFerium 1k is indicated for:
- Iron Deficiency Anemia: Particularly in patients with chronic kidney disease, malabsorption syndromes, or those undergoing hemodialysis.
- Preoperative or Postoperative Anemia: To correct anemia before surgery or to manage post-surgical recovery.
Ferium 1k delivers iron intravenously, allowing for rapid absorption and utilization by the body. Once administered, iron is incorporated into hemoglobin, which is crucial for oxygen transport in the blood.
Dosage and Administration- Standard Dosage: The typical dose is 1000 mg of iron administered intravenously, though specific dosing may vary based on the patient's condition and response.
- Administration: Administered slowly via intravenous infusion to minimize the risk of adverse reactions.
Ferium 1k is contraindicated in:
- Hypersensitivity: Known allergy to iron preparations.
- Non-Iron Deficiency Anemia: Such as anemia of chronic disease without iron deficiency.
- Hemochromatosis or Hemosiderosis: Conditions leading to iron overload.
- Allergic Reactions: Monitor patients for signs of allergic reactions during and after administration.
- Overdose: Iron overload can occur; use caution in patients with a history of iron overload disorders.
- Infections: Iron can facilitate bacterial growth, so be vigilant in patients with infections.
Common side effects may include:
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Fever
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Iron overload syndromes
- Hypotension during infusion
Ferium 1k may interact with other medications, especially those that also contain iron or affect iron metabolism. Patients should inform their healthcare provider about all medications and supplements they are taking.
Storage InstructionsStore Ferium 1k Injection in a cool, dry place, away from light. Protect from freezing. Keep out of reach of children.
Patient Counseling Information- Advise patients to report any unusual symptoms, especially signs of allergic reactions or gastrointestinal distress.
- Discuss the importance of follow-up appointments to monitor iron levels and overall health.
- Inform patients about potential side effects and when to seek medical attention.
Ferium 1k Injection is an effective treatment for iron deficiency anemia, providing necessary iron directly into the bloodstream. Proper administration and monitoring are vital for ensuring patient safety and treatment efficacy.
Yes! I am InterestedRequest A Callback
Basalog 100 IU Injection
Product Price: Rs 500 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 100 IU/ml |
| Form | Injection |
| Composition | Insulin Glargine Injection |
| Brand | Basalog |
| Manufacturer | Biocon Biologics |
| Storage Conditions | Store in a refrigerator (2 - 8 DegreeC). Do not freeze. |
Basalog is an injectable formulation of insulin glargine, a long-acting insulin used to manage blood glucose levels in individuals with diabetes mellitus. It is designed to provide a steady release of insulin over a 24-hour period, helping to control blood sugar levels throughout the day and night.
IndicationsBasalog is indicated for:
- Type 1 Diabetes: As a basal insulin to control blood glucose levels in adults and children.
- Type 2 Diabetes: For patients who require insulin therapy to achieve optimal glycemic control, often used in conjunction with oral antidiabetic medications.
Insulin glargine is a modified form of human insulin that has a prolonged duration of action. It works by facilitating the uptake of glucose into cells, particularly in muscle and fat tissues, while inhibiting glucose production in the liver. This helps to lower blood sugar levels effectively.
Dosage and Administration- Standard Dosage: The initial dose is individualized based on the patient's needs, typically starting at 10 IU once daily, with adjustments made based on blood glucose monitoring.
- Administration: Administered via subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy.
Basalog is contraindicated in:
- Hypoglycemia: Known hypersensitivity to insulin glargine or any components of the formulation.
- Severe Hypoglycemia: Patients experiencing severe low blood sugar levels should not use this medication.
- Hypoglycemia: Monitor blood glucose levels regularly, especially during changes in diet, exercise, or medication regimen, as there is a risk of hypoglycemia.
- Allergic Reactions: Be aware of potential allergic reactions, including localized reactions at the injection site.
- Renal or Hepatic Impairment: Dosage adjustments may be necessary for patients with kidney or liver dysfunction.
Common side effects may include:
- Hypoglycemia
- Injection site reactions (redness, swelling, itching)
- Weight gain
- Edema (swelling)
Serious side effects can include:
- Severe hypoglycemia (leading to loss of consciousness or seizures)
- Allergic reactions (anaphylaxis)
- Hypokalemia (low potassium levels)
Basalog may interact with other medications that affect blood glucose levels, including corticosteroids, diuretics, and other antidiabetic drugs. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Basalog (100 IU Injection) in the refrigerator at 2°C to 8°C (36°F to 46°F) until opened. Once in use, it can be kept at room temperature for up to 28 days. Protect from light.
Patient Counseling Information- Advise patients on recognizing the signs and symptoms of hypoglycemia and the importance of monitoring blood glucose levels regularly.
- Discuss the importance of adhering to the prescribed insulin regimen and diet.
- Educate patients about proper injection techniques and site rotation.
Basalog (100 IU Injection) is an essential medication for managing diabetes, providing long-lasting blood glucose control. Proper administration and monitoring are crucial for maximizing treatment efficacy and minimizing risks.
Yes! I am InterestedRequest A Callback
Luprova 3.75mg Injection
Product Price: Rs 4,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 3.75 mg |
| Formulation Type | Suspension |
| Packaging Type | Vial |
| Brand | Luprova |
| Manufacturer | Celon |
| Shelf Life | 35 Months |
| Composition | Leuprolide |
| Storage | Store at a temperature not exceeding 25 Degree c |
| Type Of Medicines | Allopathic |
Yes! I am InterestedRequest A Callback
Luprova Leuprolide 11.25mg Injection
Product Price: Rs 5,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 11.25 mg |
| Packaging Type | Vial |
| Country of Origin | Made in India |
| Composition | Leuprolide Acetate 11.25 mg |
| Brand | Luprova |
| Manufacturer | Celon |
| Shelf Life | 24 To 36 Month |
| Storage | Store at a temperature not exceeding 25 Degree c |
| Type Of Medicines | Allopathic |
Yes! I am InterestedRequest A Callback
Progynon Depot Injection
Product Price: Rs 250 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 10 mg |
| Packaging Size | 10 Ampoules/Box |
| Composition | Estradiol Valerate 10mg |
| Injectable Form | Liquid |
| Manufacturer | Zydus Cadila |
| Packaging Type | 10 Vial of 1ml |
| Country of Origin | Made in India |
| Brand Name | Progynon |
Progynon Depot is an injectable formulation that contains Estradiol valerate, a form of estrogen. It is primarily used in hormone replacement therapy (HRT) and other conditions related to estrogen deficiency.
IndicationsProgynon Depot is indicated for:
- Menopausal Symptoms: Relief of vasomotor symptoms (hot flashes, night sweats) associated with menopause.
- Hormonal Replacement Therapy: Treatment of estrogen deficiency in postmenopausal women.
- Amenorrhea: Management of primary or secondary amenorrhea due to hormonal imbalances.
- Contraceptive Use: Used in combination with progestins for contraception.
Estradiol valerate acts by binding to estrogen receptors in various tissues, leading to a variety of physiological effects that help restore hormonal balance. It alleviates symptoms associated with low estrogen levels and helps maintain the health of the reproductive system.
Dosage and Administration- Standard Dosage: The typical dosage of Progynon Depot is 5 to 10 mg, administered intramuscularly. The frequency of administration may vary based on the indication but is usually every 4 to 12 weeks.
- Administration: Administer via deep intramuscular injection. Rotate injection sites to minimize local reactions.
Progynon Depot is contraindicated in:
- Hypersensitivity: Known allergy to estradiol valerate or any component of the formulation.
- History of Thromboembolic Disorders: Patients with a history of deep vein thrombosis, pulmonary embolism, or stroke.
- Hormone-Sensitive Cancers: Such as breast or uterine cancer.
- Thromboembolic Risk: Monitor for signs of thromboembolism, especially in patients with risk factors.
- Endometrial Hyperplasia: Long-term estrogen therapy may increase the risk of endometrial hyperplasia and carcinoma; progestin should be added for women with a uterus.
- Liver Function: Use with caution in patients with liver disease.
Common side effects may include:
- Headache
- Nausea
- Breast tenderness
- Mood changes
- Injection site reactions
Serious side effects can include:
- Venous thromboembolism
- Heart attack or stroke
- Liver dysfunction
Progynon Depot may interact with other medications that affect liver enzymes or hormonal therapies. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Progynon Depot Injection at room temperature, protected from light. Do not freeze.
Patient Counseling Information- Educate patients about the importance of regular follow-up appointments to monitor therapy effectiveness and side effects.
- Discuss potential side effects and when to seek medical attention.
- Advise patients on the importance of a healthy lifestyle and managing cardiovascular risk factors.
Progynon Depot Injection is a valuable treatment option for managing menopausal symptoms and other conditions related to estrogen deficiency. Proper administration and monitoring are essential to maximize therapeutic benefits while minimizing risks.
Yes! I am InterestedRequest A Callback
Darbepoetin Alfa Injection (Kabidarba 40 Injection )
Product Price: Rs 1,250 / BoxGet Best Price
Product Brochure
Product Details:
| Strength | 40 mcg |
| Brand | Kabidarba |
| Dose Form | PFS |
| Pack Size | 0.40 ml |
| Composition | Darbepoetin alfa-40 mcg |
| Brand Name | Kabidarba |
| Manufacturer | Fresenius Kabi India Pvt Ltd |
| Treatment | Anaemia (in cancer and chronic kidney disease) |
Kabidarba is an injectable formulation of Darbepoetin Alfa, a recombinant human erythropoietin that stimulates erythropoiesis (red blood cell production). It is primarily used to treat anemia associated with chronic kidney disease and certain cancer treatments.
IndicationsKabidarba is indicated for:
- Anemia in Chronic Kidney Disease (CKD): Effective in patients on dialysis and those not on dialysis.
- Chemotherapy-Induced Anemia: Used to treat anemia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.
Darbepoetin Alfa binds to the erythropoietin receptor on erythroid progenitor cells in the bone marrow, stimulating the production and differentiation of red blood cells. This leads to increased hemoglobin levels and improved oxygen delivery to tissues.
Dosage and Administration- Standard Dosage: The typical starting dose for adults is 0.45 mcg/kg, administered subcutaneously or intravenously once every 1 to 4 weeks, depending on the clinical scenario.
- Administration: Administer the injection under the skin or directly into a vein. Dosage adjustments may be necessary based on hemoglobin levels and patient response.
Kabidarba is contraindicated in:
- Hypersensitivity: Known allergy to darbepoetin alfa or any components of the formulation.
- Uncontrolled Hypertension: Should not be used in patients with poorly controlled hypertension.
- Cardiovascular Events: Use caution in patients with a history of cardiovascular disease, as erythropoiesis-stimulating agents may increase the risk of serious cardiovascular events.
- Hemoglobin Levels: Monitor hemoglobin regularly to avoid excessive increases, which can lead to thromboembolic events.
- Tumor Progression: In patients with cancer, there is a risk that darbepoetin alfa may promote tumor growth; use judiciously in this population.
Common side effects may include:
- Hypertension
- Headache
- Fatigue
- Nausea
- Injection site reactions
Serious side effects can include:
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Severe allergic reactions (anaphylaxis)
- Worsening of hypertension
Darbepoetin Alfa may interact with other medications that affect blood pressure or blood cell counts. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Kabidarba (Darbepoetin Alfa Injection 40 mg) in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
Patient Counseling Information- Educate patients about the importance of regular blood tests to monitor hemoglobin levels and blood pressure.
- Discuss potential side effects and instruct patients on when to seek medical attention, especially for symptoms of cardiovascular events.
- Advise patients on proper injection techniques and to rotate injection sites to reduce discomfort.
Kabidarba (Darbepoetin Alfa Injection 40 mg) is an effective treatment for anemia associated with chronic kidney disease and chemotherapy. Careful administration and monitoring are crucial to ensure patient safety and optimize therapeutic outcomes.
Yes! I am InterestedRequest A Callback
Amino Acid Injection (Celemin 5-S Injection)
Product Price: Rs 250 / BottleGet Best Price
Product Brochure
Product Details:
| Application | Human Nutrition |
| Package Size | 500 ml |
| Form | Liquid |
| Concentration | 5% |
| Purity | 10% |
| Packaging Size | 500 ml |
| Packaging Type | Bottle |
| Brand | Celemin |
| Packaging | 500 ml infusion in 1 Bottle |
| Composition | Amino Acid-5%W/V + Sorbitol-5%W/V |
| Manufacturer | Claris Lifesciences Ltd |
Celemin 5-S is a sterile intravenous amino acid injection designed to provide essential amino acids necessary for various physiological functions. It supports metabolic processes in patients unable to consume food normally due to medical conditions.
IndicationsCelemin 5-S is indicated for:
- Parenteral Nutrition: Nutritional supplementation for patients unable to eat orally.
- Postoperative Recovery: Assisting recovery in surgical patients with elevated protein needs.
- Catabolic States: Supporting patients in trauma, burns, or severe infections where protein requirements are increased.
Celemin 5-S typically contains a blend of essential and non-essential amino acids, which may include:
- L-Alanine
- L-Arginine
- L-Aspartic Acid
- L-Glutamic Acid
- L-Leucine
- L-Isoleucine
- L-Valine
Amino acids are critical for:
- Protein synthesis
- Hormone production
- Immune function
- Tissue repair and growth
Administering Celemin 5-S directly into the bloodstream helps maintain nitrogen balance and supports overall health.
Dosage and Administration- Dosage: Varies based on the patient’s condition, age, weight, and nutritional needs. Determined by a healthcare professional.
- Administration: Given intravenously, typically as part of total parenteral nutrition (TPN). Infusion rates and duration should be individualized.
Celemin 5-S is contraindicated in:
- Hypersensitivity: Known allergy to components of the injection.
- Severe Renal Impairment: Risk of amino acid accumulation.
- Metabolic Disorders: Conditions that affect amino acid metabolism.
- Fluid Overload: Monitor for signs, especially in patients with heart or kidney issues.
- Electrolyte Imbalances: Regularly check levels to prevent complications.
- Infusion Reactions: Observe for allergic reactions or complications at the infusion site.
Common side effects may include:
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions (redness, swelling)
Serious side effects can include:
- Anaphylaxis
- Electrolyte imbalances
- Hyperammonemia (especially in liver dysfunction)
Celemin 5-S may interact with medications that affect protein metabolism. Patients should inform healthcare providers of all medications and supplements.
Storage InstructionsStore Celemin 5-S (Amino Acid Injection) in a cool, dry place away from light. Follow specific storage guidelines provided on the product label.
Patient Counseling Information- Educate patients and caregivers on monitoring for side effects during intravenous administration.
- Discuss potential allergic reactions and advise when to seek medical attention.
- Emphasize the importance of regular follow-up and laboratory monitoring.
Celemin 5-S (Amino Acid Injection) is vital for providing nutritional support to patients who cannot meet their needs orally. Proper administration and monitoring are essential for safety and efficacy.
Yes! I am InterestedRequest A Callback
Omnipaque 350 Mg 100 Ml Injection
Product Price: Rs 1,350 / BottleGet Best Price
Product Brochure
Product Details:
| Strength (mgI/ml) | 350 mgI/ml |
| Strength | 350 mg |
| Volume | 100 ml |
| Packaging Type | Bottle |
| Composition | Iohexol 350 mg |
| Packaging Size | 100 ml |
| Manufacturer | GE Healthcare |
| Brand Name | Omnipaque |
Omnipaque 350 mg/100 mL Injection is a non-ionic iodinated contrast media used in various imaging procedures. If you are seeking effective options for diagnostic imaging, Omnipaque is designed to enhance the visibility of internal structures in X-ray and CT scans, helping healthcare providers make accurate diagnoses.
What is Omnipaque?Omnipaque contains Iohexol, a water-soluble, iodinated compound. It is widely used as a contrast agent in radiological procedures due to its excellent safety profile and efficacy in providing clear images.
IndicationsOmnipaque is indicated for:
- Intravenous Use: Enhancing the contrast of vascular structures and organs during X-ray and CT imaging.
- Intrathecal Use: Improving visualization of the central nervous system during lumbar punctures or myelography.
- Arteriography: Facilitating the assessment of blood vessels in various regions of the body.
When injected, Omnipaque absorbs X-rays, allowing for enhanced visualization of blood vessels and soft tissues during imaging procedures. This contrast helps radiologists identify abnormalities such as tumors, lesions, or vascular conditions.
Dosage and Administration- Dosage: The dosage of Omnipaque is determined by the type of imaging procedure and the patient's weight. Common doses range from 50 to 150 mL depending on the specific application.
- Administration: Omnipaque is administered via injection by a qualified healthcare professional, either intravenously or intrathecally.
Omnipaque is contraindicated in:
- Hypersensitivity: Known allergy to Iohexol or any components of the formulation.
- Severe Renal Impairment: Caution is advised in patients with kidney problems.
- Renal Function: Monitor renal function, especially in patients with pre-existing kidney disease, as contrast-induced nephropathy can occur.
- Thyroid Function: Patients with thyroid disorders should be monitored, as iodinated contrast media can affect thyroid hormone levels.
- Dehydration: Ensure adequate hydration in patients before and after the administration of Omnipaque.
Common side effects may include:
- Injection site reactions (pain, swelling)
- Nausea or vomiting
- Warmth or flushing
- Mild headache
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Contrast-induced nephropathy
- Thyroid dysfunction
Omnipaque may interact with other medications, particularly those affecting kidney function or diuretics. Inform your healthcare provider about all medications and supplements you are taking.
Storage InstructionsStore Omnipaque 350 mg/100 mL Injection at room temperature, away from light. Protect from freezing and keep out of reach of children.
Patient Counseling Information- Educate patients about the purpose of the contrast agent and the imaging procedure.
- Discuss potential side effects and advise patients to report any severe reactions immediately.
- Ensure patients understand the importance of hydration before and after the procedure.
Omnipaque 350 mg/100 mL Injection is a crucial tool in modern diagnostic imaging, providing enhanced visualization for accurate assessments. Its safety and effectiveness make it a preferred choice for healthcare providers worldwide.
Yes! I am InterestedRequest A Callback
Emtreo Cancer Injection
Product Price: Rs 12,500 / VialGet Best Price
Product Brochure
Product Details:
| Dose | 5 g/Vial |
| Pack Type | 100 ml Injection in 1 Vial |
| Composition | Treosulfan 5000mg |
| Brand | Emtreo |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Treatment | Ovarian cancer |
| Medicine brand | Emtreo |
| Medicine form | Injection |
| Medicine name | Treosulfan injection |
| Medicine strength | 5g/vial |
| Packaging type | Vial |
Yes! I am InterestedRequest A Callback
Gemcitabine (Gemtero 200 Mg Injection)
Product Price: Rs 650 / VialGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 200 mg |
| Packaging Type | Vial |
| Manufacturer | Hetero Drugs Ltd |
| Prescription/Non prescription | Prescription |
| Brand Name | Gemcitabine |
Gemcitabine is primarily used for the treatment of various cancers, including:
- Pancreatic cancer
- Non-small cell lung cancer (NSCLC)
- Breast cancer
- Bladder cancer
Gemcitabine is a nucleoside analog that interferes with DNA synthesis. It gets incorporated into the DNA of rapidly dividing cancer cells, ultimately leading to cell death. By inhibiting DNA polymerase, it disrupts the cancer cell's ability to replicate and repair DNA.
Dosage and Administration:- Dosage: The dosage of gemcitabine varies based on the type of cancer, treatment regimen, and patient condition. Typical starting doses range from 800 mg/m² to 1,000 mg/m², administered weekly or every other week.
- Administration: Administered via slow intravenous infusion over 30 minutes. Dosage may be adjusted based on patient tolerance and response.
- Hypersensitivity to gemcitabine or any component of the formulation.
- Severe bone marrow suppression.
- Bone Marrow Suppression: Monitor blood counts regularly, as gemcitabine can cause neutropenia, anemia, and thrombocytopenia.
- Liver Function: Caution in patients with liver impairment; dosage adjustments may be necessary.
- Fluid Retention: Monitor for signs of fluid retention and pulmonary symptoms.
Common Side Effects:
- Nausea and vomiting
- Fatigue
- Low blood cell counts (neutropenia, anemia, thrombocytopenia)
- Liver enzyme elevations
Serious Side Effects:
- Severe allergic reactions
- Respiratory distress
- Tumor lysis syndrome (in certain patients)
Gemcitabine may interact with other medications that can affect bone marrow function or are hepatically metabolized. Patients should inform their healthcare provider about all medications they are taking.
Storage:- Store in a cool, dry place. Follow specific manufacturer guidelines for storage conditions.
- Advise patients to report any signs of infection, unusual bleeding, or severe fatigue.
- Discuss potential side effects and the importance of regular blood tests during treatment.
- Encourage adherence to the prescribed treatment plan for optimal effectiveness.
Gemcitabine is a potent chemotherapy agent used in various cancers, requiring careful monitoring for side effects and adjustments based on individual patient responses. Always consult a healthcare professional for personalized treatment advice.
Yes! I am InterestedRequest A Callback
Lupitux Cetuximab 100mg/20ml injection
Product Price: Rs 8,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Packaging Size | 20 ml |
| Brand | Lupitux |
| Manufacturer | Lupin Ltd |
| Packaging Type | Vial |
| Treatment | Head and neck cancer and cancer of colon and rectum |
Lupitux (Cetuximab) is primarily indicated for:
- Treatment of patients with:
- Metastatic colorectal cancer (mCRC) in combination with chemotherapy for those whose tumors express the epidermal growth factor receptor (EGFR).
- Head and neck squamous cell carcinoma (HNSCC), in combination with radiation therapy or as monotherapy for recurrent or metastatic disease.
Cetuximab is a monoclonal antibody that binds specifically to the extracellular domain of the EGFR. By blocking EGFR activation, it inhibits downstream signaling pathways that promote cell proliferation and survival, ultimately leading to reduced tumor growth.
Dosage and Administration:- Dosage: The typical starting dose for metastatic colorectal cancer is 400 mg/m² administered as a single intravenous infusion, followed by 250 mg/m² weekly. For head and neck cancer, the dosing may vary based on the treatment regimen.
- Administration: Cetuximab is administered as an intravenous infusion. The first infusion should be given slowly (over 120 minutes) to monitor for infusion-related reactions; subsequent infusions may be given over 60 minutes if well tolerated.
- Hypersensitivity to cetuximab or any component of the formulation.
- History of severe infusion reactions to cetuximab.
- Infusion Reactions: Monitor closely during the first infusion and consider premedication for patients with a history of infusion reactions.
- Skin Reactions: Acneiform rash is common; proper skin care and management should be discussed.
- Cardiopulmonary Events: Monitor for potential cardiopulmonary complications, particularly in patients with a history of cardiopulmonary disease.
Common Side Effects:
- Acneiform rash
- Nausea
- Diarrhea
- Fatigue
- Infusion-related reactions (fever, chills)
Serious Side Effects:
- Severe allergic reactions
- Electrolyte imbalances (especially hypomagnesemia)
- Pulmonary complications (e.g., interstitial lung disease)
Cetuximab may interact with other medications, particularly those that can cause electrolyte imbalances or affect liver function. Patients should inform their healthcare provider about all medications and supplements they are taking.
Storage:- Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
- Advise patients to report any signs of allergic reactions or severe skin reactions.
- Discuss the importance of monitoring for side effects and regular follow-up appointments.
- Educate about potential skin care routines to manage acneiform rash.
Lupitux (Cetuximab) is an effective targeted therapy for certain cancers, requiring careful monitoring for infusion reactions and skin side effects. Always consult a healthcare professional for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Cetuxa Cetuximab 100mg/20ml injection
Product Price: Rs 7,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Brand | Cetuxa |
| Manufacturer | Alkem Laboratories Ltd |
| Packaging Size | 20 ml Injection in 1 Vial |
| Treatment | Head and neck cancer |
Cetuximab is primarily indicated for:
- Metastatic colorectal cancer (mCRC) in combination with chemotherapy for patients whose tumors express the epidermal growth factor receptor (EGFR).
- Head and neck squamous cell carcinoma (HNSCC) in combination with radiation therapy or as monotherapy for recurrent or metastatic disease.
Cetuximab is a monocal antibody that specifically targets the epidermal growth factor receptor (EGFR). By binding to EGFR, it inhibits the receptor's activation, blocking downstream signaling pathways that promote tumor growth and survival.
Dosage and Administration:- Dosage: The initial dose for metastatic colorectal cancer is typically 400 mg/m² administered as an intravenous infusion, followed by 250 mg/m² weekly. For head and neck cancer, dosing may vary based on specific treatment protocols.
- Administration: Administered via intravenous infusion. The first infusion should be given slowly (over 120 minutes) to monitor for infusion-related reactions; subsequent infusions can be administered over 60 minutes if well tolerated.
- Hypersensitivity to cetuximab or any component of the formulation.
- History of severe infusion reactions.
- Infusion Reactions: Close monitoring during the first infusion is essential; premedication may be considered for those with a history of reactions.
- Skin Reactions: Acneiform rash is a common side effect; patients should be advised on skin care.
- Electrolyte Imbalances: Monitor for hypomagnesemia and other electrolyte disturbances.
Common Side Effects:
- Acneiform rash
- Nausea
- Diarrhea
- Fatigue
- Infusion-related reactions (e.g., fever, chills)
Serious Side Effects:
- Severe allergic reactions
- Electrolyte imbalances (especially hypomagnesemia)
- Pulmonary complications (e.g., interstitial lung disease)
Cetuximab may interact with other medications that affect electrolyte levels or liver function. Patients should provide their healthcare provider with a complete list of medications and supplements.
Storage:- Store at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
- Advise patients to report any signs of allergic reactions, severe skin reactions, or respiratory issues.
- Discuss the importance of monitoring for side effects and attending regular follow-up appointments.
- Educate on skincare to help manage acneiform rash.
Cetuximab (Cetuxa) is an effective targeted therapy for certain cancers, requiring close monitoring for infusion reactions and skin-related side effects. Always consult a healthcare professional for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Paclitaxel Abraxane 100mg injection Celgene 100mg Injection
Product Price: Rs 12,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Pack Type | Vial |
| Brand Name | Abraxane |
| Manufacturer | Celgene |
| Treatment | Various cancers of the female reproductive system, lungs, and breast |
Abraxane is primarily indicated for the treatment of:
- Metastatic breast cancer, in combination with other therapies.
- Non-small cell lung cancer (NSCLC), in combination with carboplatin.
- Metastatic pancreatic cancer, in combination with gemcitabine.
Paclitaxel is a chemotherapy drug that belongs to the class of taxanes. It works by inhibiting cell division (mitosis) by stabilizing the microtubules, preventing their depolymerization. This action leads to the accumulation of cells in the mitotic phase, ultimately resulting in cell death.
Dosage and Administration:- Dosage: The typical dose of Abraxane for breast cancer is 100 mg/m² administered as an intravenous infusion on days 1, 8, and 15 of a 28-day cycle. Dosages may vary based on the specific type of cancer and treatment regimen.
- Administration: Administer as an intravenous infusion over 30 minutes. It should not be diluted or mixed with other medications.
- Hypersensitivity to paclitaxel, polysorbate 80, or any component of the formulation.
- Severe bone marrow suppression.
- Bone Marrow Suppression: Monitor complete blood counts regularly; dose adjustments may be necessary based on blood cell counts.
- Hypersensitivity Reactions: Monitor for allergic reactions, particularly during the first infusion. Pre-medication may be required for some patients.
- Neuropathy: Peripheral neuropathy can occur; assess neurological status regularly.
Common Side Effects:
- Nausea and vomiting
- Fatigue
- Hair loss (alopecia)
- Peripheral neuropathy
- Low blood cell counts (anemia, neutropenia)
Serious Side Effects:
- Severe allergic reactions
- Infections due to neutropenia
- Cardiac events (e.g., arrhythmias)
- Severe skin reactions
Abraxane may interact with other medications that affect liver enzymes or those that may increase the risk of neutropenia. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage:- Store at room temperature (20°C to 25°C or 68°F to 77°F) and protect from light. Do not freeze.
- Advise patients to report any signs of allergic reactions, infections, or unusual side effects.
- Discuss the importance of regular blood tests to monitor blood counts.
- Inform patients about possible side effects and the need for supportive care, such as anti-nausea medications.
Abraxane (Paclitaxel) is an effective chemotherapy treatment for various cancers, necessitating careful monitoring for side effects and dose adjustments as needed. Always consult a healthcare professional for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Abevmy Bevacizumab 100mg /4ml Injection
Product Price: Rs 9,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg/4 ml |
| Volume | 4 ml |
| Pharmaceutical Form | Solution for Infusion |
| Brand | Abevmy |
| Packaging Size | 4 ml in 1 vial |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Treatment | Cancer of colon and rectum |
Abevmy (Bevacizumab) is indicated for the treatment of:
- Metastatic colorectal cancer (mCRC) in combination with chemotherapy.
- Non-small cell lung cancer (NSCLC), in combination with chemotherapy.
- Glioblastoma, in combination with other treatments.
- Metastatic breast cancer, in combination with chemotherapy.
- Cervical cancer, in combination with paclitaxel and cisplatin.
- Ovarian cancer, in combination with carboplatin and paclitaxel.
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting its interaction with the VEGF receptor. This action prevents the formation of new blood vessels (angiogenesis) that tumors need for growth and metastasis.
Dosage and Administration:- Dosage: The recommended dose for most indications is 5 mg/kg to 10 mg/kg administered as an intravenous infusion, depending on the specific cancer type and treatment regimen.
- Administration: Administer as an intravenous infusion over 30 to 90 minutes. The initial infusion should be given slowly, and subsequent infusions can be given at a faster rate if well tolerated.
- Hypersensitivity to bevacizumab or any component of the formulation.
- History of serious bleeding or gastrointestinal perforation.
- Pregnancy (Category C) and breastfeeding.
- Bleeding Risks: Monitor for signs of severe bleeding, especially in patients with a history of bleeding disorders.
- Gastrointestinal Perforation: Use caution in patients with a history of gastrointestinal conditions.
- Hypertension: Monitor blood pressure regularly; manage any hypertension aggressively.
- Wound Healing: Bevacizumab may impair wound healing; consider delaying treatment in patients undergoing surgery.
Common Side Effects:
- Hypertension
- Fatigue
- Nausea
- Vomiting
- Diarrhea
Serious Side Effects:
- Severe allergic reactions
- Gastrointestinal perforations
- Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism)
- Wound healing complications
Bevacizumab may interact with other medications, particularly those that affect bleeding risk or blood pressure. Patients should inform their healthcare provider about all medications they are taking.
Storage:- Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
- Advise patients to report any signs of severe bleeding, gastrointestinal issues, or high blood pressure.
- Discuss the importance of regular monitoring and follow-up appointments.
- Inform patients about possible side effects and when to seek medical attention.
Abevmy (Bevacizumab) is a targeted therapy effective for various cancers, requiring careful monitoring for side effects and contraindications. Always consult a healthcare professional for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Paclitaxel Injection (zaxol 30mg Injection)
Product Price: Rs 1,150 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 30 mg |
| Pack Size | 5 ml |
| Pack Type | Vial |
| Brand Name | Zaxol |
| Manufacturer | Zuvius Life Sciences |
Paclitaxel, marketed as Zaxol 30 mg, is a chemotherapy medication used primarily in the treatment of various cancers, including breast cancer, non-small cell lung cancer (NSCLC), ovarian cancer, and Kaposi's sarcoma. It belongs to the class of drugs known as taxanes and works by inhibiting cancer cell growth.
Indications for PaclitaxelPaclitaxel is indicated for:
- Breast Cancer: Often used in combination with other chemotherapy agents for both early and advanced stages.
- Non-Small Cell Lung Cancer: Administered as a first-line treatment or in combination with other agents.
- Ovarian Cancer: Used as part of combination therapy for advanced disease.
- Kaposi's Sarcoma: Effective in treating patients with this condition, particularly in those with HIV/AIDS.
Paclitaxel works by stabilizing the microtubules in the cell, preventing them from disassembling during mitosis. This disruption leads to cell cycle arrest and ultimately results in cancer cell death.
Dosage and Administration- Standard Dosage: The recommended dose of Paclitaxel (Zaxol 30 mg) can vary based on the type of cancer and the treatment regimen. Commonly, doses range from 80 mg/m² to 175 mg/m².
- Administration: Paclitaxel is administered intravenously. The infusion rate and duration will depend on the specific treatment plan, typically over 3 to 24 hours.
Paclitaxel should not be used in:
- Hypersensitivity: Patients with known allergies to Paclitaxel or any of its components, including polyoxyl castor oil.
- Severe Neutropenia: Avoid use in patients with low white blood cell counts.
- Myelosuppression: Monitor blood counts regularly due to the risk of neutropenia, thrombocytopenia, and anemia.
- Cardiovascular Effects: Patients with pre-existing heart conditions should be monitored closely.
- Hypersensitivity Reactions: Premedication with corticosteroids and antihistamines may be necessary to prevent allergic reactions.
Common side effects of Paclitaxel may include:
- Nausea and vomiting
- Hair loss (alopecia)
- Fatigue
- Peripheral neuropathy
- Diarrhea
Serious side effects can include:
- Severe allergic reactions
- Myelosuppression (low blood cell counts)
- Infections due to low white blood cells
- Heart problems
Paclitaxel may interact with other medications, particularly those affecting liver enzymes (CYP450). Always inform your healthcare provider about all medications being taken, including over-the-counter drugs and supplements.
Storage InstructionsStore Paclitaxel Injection (Zaxol 30 mg) at room temperature, away from light, and protect from moisture. Do not freeze.
Patient Counseling Information- Advise patients to report any signs of infection, unusual bleeding, or allergic reactions.
- Discuss the potential side effects and the importance of adhering to the prescribed treatment schedule.
- Encourage patients to attend regular follow-up appointments to monitor their response to therapy.
Paclitaxel Injection (Zaxol 30 mg) is an important treatment option for various types of cancer. Patients should work closely with their healthcare providers to manage potential side effects and ensure optimal treatment outcomes.
Yes! I am InterestedRequest A Callback
Paclitaxel Injection (Pacget 260mg Injection)
Product Price: Rs 2,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 260 mg |
| Pack Size | 43.4 ml |
| Brand Name | Pacget |
| Manufacturer | GLS Pharma Ltd |
| Treatment | Breast disease |
Paclitaxel, marketed as Pacget 260 mg, is a chemotherapy medication used to treat various cancers, including breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and Kaposi's sarcoma. It belongs to the taxane class of drugs, which disrupt normal microtubule function, critical for cell division.
IndicationsPaclitaxel is indicated for:
- Breast Cancer: Effective in early and metastatic stages, often used with other agents.
- Ovarian Cancer: Administered as part of combination therapy for advanced cases.
- Non-Small Cell Lung Cancer (NSCLC): Used as a first-line treatment, alone or with cisplatin.
- Kaposi's Sarcoma: Beneficial for patients with HIV/AIDS.
Paclitaxel stabilizes microtubules during cell division, preventing disassembly. This leads to cell cycle arrest, inhibiting cancer cell proliferation and inducing apoptosis (programmed cell death), reducing tumor growth.
Dosage and Administration- Standard Dosage: The dosage of Paclitaxel (Pacget 260 mg) varies based on cancer type, typically ranging from 80 mg/m² to 175 mg/m².
- Administration: Paclitaxel is given intravenously, with infusion times from 3 to 24 hours based on the regimen. Adhering to the infusion schedule is crucial.
Paclitaxel is contraindicated in:
- Hypersensitivity: Known allergies to Paclitaxel or its components, especially polyoxyl castor oil.
- Severe Neutropenia: Patients with low white blood cell counts should not receive this medication.
- Myelosuppression: Regular monitoring of blood counts is essential due to risks of neutropenia, anemia, and thrombocytopenia. Dose adjustments may be necessary.
- Hypersensitivity Reactions: Premedication with antihistamines and corticosteroids is often recommended to minimize allergic reactions.
- Cardiovascular Effects: Patients with heart conditions should be monitored closely for complications.
Common side effects may include:
- Nausea and vomiting
- Hair loss (alopecia)
- Fatigue
- Peripheral neuropathy (numbness or tingling)
- Diarrhea
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Myelosuppression (low blood cell counts)
- Increased risk of infections
- Cardiac complications, such as arrhythmias
Paclitaxel may interact with medications affecting liver enzymes (CYP450). Patients should inform their healthcare provider of all medications, including over-the-counter drugs and supplements.
Storage InstructionsStore Paclitaxel Injection (Pacget 260 mg) at room temperature, between 20°C and 25°C (68°F to 77°F). Protect from light and moisture, and do not freeze.
Patient Counseling Information- Advise patients to report any signs of infection, unusual bleeding, or allergic reactions.
- Discuss potential side effects and the importance of adhering to the treatment regimen.
- Encourage regular follow-up appointments to monitor effectiveness and manage side effects.
Paclitaxel Injection (Pacget 260 mg) is a vital treatment for various cancers, requiring careful monitoring and adherence to protocols. Open communication with healthcare providers is essential for effectively managing side effects and optimizing treatment outcomes.
Yes! I am InterestedRequest A Callback
Gemcitabine Injection (Gemolife NV 1000 mg)
Product Price: Rs 4,050 / VialGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 1000 mg |
| Form | Injection |
| Packaging Type | Vial |
| Prescription/Non prescription | Prescription |
| Manufacturer | Axiommax Oncology Pvt Ltd |
| Usage/Application | Hospital |
Gemcitabine Injection (Gemolife NV 1000)
Description:
Gemcitabine (Gemolife NV 1000) is an injectable chemotherapy medication that contains Gemcitabine, a nucleoside analogue. It interferes with DNA synthesis, effectively inhibiting the growth and proliferation of cancer cells.
- Pancreatic Cancer: Commonly used for metastatic pancreatic cancer, often in combination with other therapies.
- Non-Small Cell Lung Cancer: Effective for locally advanced or metastatic non-small cell lung cancer, frequently used alongside other chemotherapy agents.
- Breast Cancer: Utilized in combination with other treatments for metastatic breast cancer.
- Bladder Cancer: Part of the treatment regimen for bladder cancer, often combined with other drugs.
- Dosage: The specific dosage is determined by the healthcare provider based on the patient's overall health and treatment plan.
- Administration: Gemcitabine is administered intravenously. The standard regimen usually involves infusions once a week for three weeks, followed by a week of rest, though this can vary based on the individual protocol.
- Nausea and vomiting
- Fatigue
- Hair loss
- Decreased blood cell counts, which may increase the risk of infections
- Liver function abnormalities
- Regular monitoring of blood counts is crucial due to the risk of myelosuppression.
- Use with caution in patients with liver or kidney impairment.
- Not recommended for use during pregnancy or while breastfeeding without consulting a healthcare provider.
Gemcitabine (Gemolife NV 1000) is an effective treatment option for various cancers, including pancreatic, lung, breast, and bladder cancers. Treatment regimens are individualized by healthcare professionals to optimize effectiveness and manage side effects.
Yes! I am InterestedRequest A Callback
Gemcitabine 1.2g Injection (Gemtaz Infusmart)
Product Price: Rs 5,000 / VialGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 1200mg |
| Form | Injection |
| Packaging Type | Vial |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| Prescription/Non prescription | Prescription |
| Composition | Gemcitabine 1200mg |
| Brand Name | Gemtaz |
Gemcitabine 1.2g Injection (Gemtaz Infusmart 1.2 g Injection)
Description:
Gemtaz Infusmart is an injection that contains Gemcitabine, a nucleoside analogue chemotherapeutic agent. It works by disrupting DNA synthesis, thereby inhibiting the growth and division of cancer cells.
- Pancreatic Cancer: Used in the treatment of metastatic pancreatic cancer, often improving survival outcomes.
- Non-Small Cell Lung Cancer: Effective for locally advanced or metastatic non-small cell lung cancer, usually in combination with other agents.
- Breast Cancer: Administered in combination with other therapies for metastatic breast cancer.
- Bladder Cancer: Utilized as part of a regimen for treating bladder cancer.
- Dosage: The specific dosage is determined by the healthcare provider based on the patient's condition and treatment plan.
- Administration: Gemtaz Infusmart is administered intravenously. The standard regimen often involves once-weekly infusions for three weeks, followed by a week of rest, although this may vary according to the treatment protocol.
- Nausea and vomiting
- Fatigue
- Hair loss
- Decreased blood cell counts, leading to an increased risk of infections
- Possible liver enzyme elevations
- Regular monitoring of blood counts is essential due to the risk of myelosuppression.
- Use with caution in patients with existing liver or kidney issues.
- Not recommended for use during pregnancy or while breastfeeding without consulting a healthcare provider.
Gemtaz Infusmart 1.2 g Injection is an important chemotherapy option for various cancers, including pancreatic, lung, breast, and bladder cancers. Treatment plans are personalized by a healthcare team to ensure the best possible outcomes and effective management of side effects.
Yes! I am InterestedRequest A Callback
Gemcitabine 1000mg Injection (MyGem 1g)
Product Price: Rs 1,800 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 1 g |
| Dose/Strength | 1000 mg |
| Injection Type | Lyophilized Powder |
| Composition | Gemcitabine |
| Packaging Type | Vial |
| Storage Condition | 2 DegreeC to 8 DegreeC |
| Prescription/Non prescription | Prescription |
| Manufacturer | Mylan |
| Form | Injection |
| Shelf Life | 24 Months to 36 Months |
| Usage/Application | Hospital |
| Country of Origin | Made in India |
MyGem Gemcitabine Injection (1 g/1000 mg)
Description:
MyGem is an injection containing Gemcitabine, a nucleoside analogue used in chemotherapy. It works by interfering with DNA synthesis, thereby inhibiting the growth and proliferation of cancer cells.
- Breast Cancer: Used as a treatment option for metastatic breast cancer, often in combination with other chemotherapy agents.
- Non-Small Cell Lung Cancer: Effective in treating locally advanced or metastatic non-small cell lung cancer.
- Pancreatic Cancer: Commonly used for metastatic pancreatic cancer, contributing to improved survival rates.
- Bladder Cancer: Employed as part of combination therapy for bladder cancer.
- Dosage: The specific dosage is determined by the healthcare provider, typically based on the patient’s body surface area and overall treatment plan.
- Administration: MyGem is administered intravenously, usually once a week for three weeks, followed by a week of rest. This cycle may vary based on the cancer type and treatment protocol.
- Nausea and vomiting
- Fatigue
- Hair loss
- Decreased blood cell counts, which can increase the risk of infections
- Liver function abnormalities
- Monitor blood counts regularly due to the risk of myelosuppression.
- Use with caution in patients with liver or kidney impairment.
- Not recommended for use during pregnancy or breastfeeding without consulting a healthcare provider.
MyGem Gemcitabine Injection (1 g/1000 mg) is an important chemotherapy option for various cancers, particularly breast, lung, pancreatic, and bladder cancers. Treatment plans are individualized by a healthcare team to optimize efficacy and manage side effects effectively.
Yes! I am InterestedRequest A Callback
Gemcitabine 200mg Injection (MyGem 200mg)
Product Price: Rs 800 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 200 mg |
| Dose/Strength | 200 mg |
| Injection Type | Lyophilized Powder |
| Composition | Gemcitabine IP |
| Packaging Type | Vial |
| Storage Condition | 2 DegreeC to 8 DegreeC |
| Manufacturer | Mylan |
| Prescription/Non prescription | Prescription |
| Form | Injection |
| Shelf Life | 24 Months to 36 Months |
| Usage/Application | Hospital |
| Country of Origin | Made in India |
MyGem 200 mg Gemcitabine Injection
Description:
MyGem is an injection containing Gemcitabine, a nucleoside analogue used in chemotherapy. It disrupts DNA synthesis in cancer cells, effectively inhibiting their growth and proliferation.
- Pancreatic Cancer: Primarily used in the treatment of metastatic pancreatic cancer.
- Non-Small Cell Lung Cancer: Often administered for locally advanced or metastatic non-small cell lung cancer.
- Breast Cancer: Utilized in combination with other therapies for metastatic breast cancer.
- Bladder Cancer: Employed as part of a combination regimen for bladder cancer.
- Dosage: The specific dosage is determined by the healthcare provider based on the patient’s treatment plan and overall health.
- Administration: MyGem is administered intravenously, typically once a week for three weeks, followed by a week of rest. Treatment schedules may vary depending on individual protocols.
- Nausea and vomiting
- Fatigue
- Hair loss
- Decreased blood cell counts, increasing the risk of infections
- Liver enzyme abnormalities
- Regular monitoring of blood counts is essential due to the risk of myelosuppression.
- Use with caution in patients with liver or kidney impairment.
- Not recommended for use during pregnancy or breastfeeding without consulting a healthcare provider.
MyGem 200 mg Gemcitabine Injection is an effective treatment option for several types of cancer, including pancreatic, lung, breast, and bladder cancers. Treatment plans are tailored by a healthcare team to ensure optimal efficacy and management of side effects.
Yes! I am InterestedRequest A Callback
Gemcitabine Injection (Gemcite 200mg)
Product Price: Rs 900 / VialGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 200 mg |
| Form | Injection |
| Packaging Type | Vial |
| Prescription/Non prescription | Prescription |
| Manufacturer | Eli Lilly and Company India Pvt Ltd |
| Brand Name | Gemcite |
Gemcitabine Injection (Gemcite 200 mg)
Description:
Gemcite is an injectable medication that contains Gemcitabine, a nucleoside analogue used in chemotherapy. It works by disrupting DNA synthesis, effectively inhibiting the growth and division of cancer cells.
- Pancreatic Cancer: Primarily used for the treatment of metastatic pancreatic cancer.
- Non-Small Cell Lung Cancer: Administered for locally advanced or metastatic non-small cell lung cancer, often in combination with other chemotherapy agents.
- Breast Cancer: Used in combination with other therapies for metastatic breast cancer.
- Bladder Cancer: Part of the treatment regimen for bladder cancer, often in combination with other drugs.
- Dosage: The specific dosage is determined by the healthcare provider based on the patient’s overall health and treatment protocol.
- Administration: Gemcite is administered intravenously. Typical treatment regimens may involve once-weekly infusions for three weeks, followed by a week of rest, although schedules may vary.
- Nausea and vomiting
- Fatigue
- Hair loss
- Decreased blood cell counts, increasing the risk of infections
- Potential liver function abnormalities
- Regular monitoring of blood counts is essential due to the risk of myelosuppression.
- Use with caution in patients with existing liver or kidney issues.
- Not recommended for use during pregnancy or breastfeeding without consulting a healthcare provider.
Gemcitabine Injection (Gemcite 200 mg) is an important chemotherapy option for treating various cancers, including pancreatic, lung, breast, and bladder cancers. Treatment plans are tailored by healthcare professionals to ensure optimal outcomes and effective management of side effects.
Yes! I am InterestedRequest A Callback
Calcium Leucovorin Injection (Biovorin 50mg Injection)
Product Price: Rs 175 / BoxGet Best Price
Product Brochure
Product Details:
| Dose/ Strength | 50 mg/5 ml |
| Brand | Biovorin |
| Manufactured By | Biochem Pharmaceutical Industries |
| Treatment | Anticipation of Harmful impacts of methotrexate |
| Composition | Calcium Leucovorin 50mg |
Calcium Leucovorin, marketed as Biovorin 50 mg, is a form of folate (vitamin B9) that acts as a rescue agent in cancer therapy, particularly in patients receiving methotrexate. It enhances the effectiveness of certain chemotherapy drugs while reducing their toxicity.
IndicationsCalcium Leucovorin is indicated for:
- Methotrexate Rescue: Used to reduce the toxicity of high-dose methotrexate therapy in cancer patients.
- Folate Deficiency: Helps to treat or prevent folate deficiency, which can occur due to various conditions.
- Combination Therapy: Used with fluorouracil in the treatment of colorectal cancer to enhance the drug's efficacy.
Calcium Leucovorin is a reduced form of folic acid that does not require enzymatic activation. It provides an active source of folate to normal cells, allowing them to synthesize DNA and RNA effectively. This action helps to mitigate the effects of methotrexate, which inhibits folate metabolism.
Dosage and Administration- Standard Dosage: The dosage of Biovorin 50 mg depends on the indication. For methotrexate rescue, typical dosing may start at 10 mg (1 vial) given orally or intravenously every 6 hours for 10 doses, adjusted based on the methotrexate serum levels.
- Administration: Administered by a healthcare professional, Calcium Leucovorin can be given intravenously or intramuscularly. It should not be mixed with other medications in the same syringe.
Calcium Leucovorin is contraindicated in:
- Hypersensitivity: Known allergy to leucovorin or any of its components.
- Vitamin B12 Deficiency: Should be used cautiously, as it may mask symptoms of this deficiency.
- Myelosuppression: Monitor blood counts regularly, especially in patients receiving concurrent chemotherapy.
- Monitoring: Regular assessment of serum methotrexate levels is essential to ensure adequate dosing and to avoid toxicity.
- Drug Interactions: Caution with other medications that may affect folate metabolism.
Common side effects may include:
- Nausea and vomiting
- Diarrhea
- Fatigue
- Rash
- Allergic reactions (rare)
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Myelosuppression (decreased blood cell counts)
- Gastrointestinal effects (e.g., severe diarrhea)
Calcium Leucovorin may interact with other medications that affect folate metabolism or have myelosuppressive effects. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Calcium Leucovorin Injection (Biovorin 50 mg) in a cool, dry place at room temperature. Protect from light and keep out of reach of children.
Patient Counseling Information- Advise patients to report any signs of allergic reactions, gastrointestinal symptoms, or unusual bleeding.
- Discuss the importance of adhering to the treatment schedule and regular blood tests for monitoring health.
- Inform patients about potential side effects and when to seek medical attention.
Calcium Leucovorin Injection (Biovorin 50 mg) is a crucial agent in cancer therapy, particularly for methotrexate rescue. Close monitoring and communication with healthcare providers are essential for managing side effects and optimizing treatment outcomes.
Yes! I am InterestedRequest A Callback
Bevacizumab Injection (Bevacirel 100mg Injection)
Product Price: Rs 8,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg/4 ml |
| Packaging Type | Vial |
| Brand | Bevacirel |
| Manufacturer | Reliance Life Sciences |
| Treatment | Kidney cancer |
Bevacizumab, commonly known as Bevacirel, is a monoclonal antibody that plays a crucial role in cancer treatment. This medication targets vascular endothelial growth factor (VEGF), which is essential for tumor growth by facilitating the formation of new blood vessels.
What is Bevacizumab?Bevacizumab is used to treat various cancers, including colorectal, lung, and breast cancer. By inhibiting VEGF, Bevacizumab effectively starves tumors of the nutrients they need to grow and spread.
How Does Bevacizumab Work?This medication works by blocking VEGF, a protein that promotes angiogenesis, the process of new blood vessel formation. By inhibiting this process, Bevacizumab reduces the tumor’s ability to thrive, leading to improved treatment outcomes.
Indications for UseBevacizumab is indicated for several types of cancer, such as metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and renal cell carcinoma. It is often administered in combination with chemotherapy to enhance its effectiveness.
Dosage and AdministrationBevacizumab is typically administered via injection every two to three weeks. The specific dosage may vary based on the type of cancer and individual patient factors, so it’s essential to follow healthcare provider recommendations.
Side Effects and ConsiderationsCommon side effects of Bevacizumab include high blood pressure, fatigue, nausea, and an increased risk of bleeding. Patients should be closely monitored for serious adverse reactions, and it’s important to discuss any concerns with healthcare providers to ensure safe treatment.
ConclusionBevacizumab (Bevacirel 100mg) is a pivotal medication in the fight against cancer. Its ability to inhibit tumor growth through anti-angiogenesis makes it a valuable option for many patients. If you or a loved one are considering Bevacizumab, consult with your healthcare professional to explore the best treatment options available.
Yes! I am InterestedRequest A Callback
100mg Abevmy Bevacizumab Injection
Product Price: Rs 10,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg/4 ml |
| Volume | 4 ml |
| Pharmaceutical Form | Solution for Infusion |
| Packaging Type | Vial |
| Brand | Abevmy |
| Country of Origin | Made in India |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Packaging Size | 4 ml in 1 vial |
| Storage Condition | Store in a refrigerator (2 - 8 DegreeC). Do not freeze. |
| Prescription/Non prescription | Prescription |
| Treatment | Cancer of colon and rectum |
| Composition | Bevacizumab 100mg |
Bevacizumab Injection 100mg/4ml (Abevmy 100 mg/4ml)
Description:
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). By blocking VEGF, it prevents the formation of new blood vessels (angiogenesis), which tumors need to grow and spread.
Indications:
- Colorectal Cancer: Used in combination with chemotherapy for metastatic colorectal cancer.
- Non-Small Cell Lung Cancer: Effective in conjunction with other treatments for metastatic non-small cell lung cancer.
- Breast Cancer: Utilized in certain cases of metastatic breast cancer.
- Kidney Cancer: Part of the treatment regimen for advanced renal cell carcinoma.
- Ovarian Cancer: Used in combination therapy for persistent, recurrent, or metastatic ovarian cancer.
Dosage and Administration:
- Dosage: Typically, the dosage is determined by the healthcare provider based on the specific cancer type and patient condition.
- Administration: Bevacizumab is administered intravenously. Commonly, it is given every two to three weeks, depending on the treatment protocol.
Common Side Effects:
- Hypertension
- Fatigue
- Gastrointestinal perforations
- Increased risk of bleeding
- Proteinuria (presence of excess protein in urine)
- Delayed wound healing
Precautions:
- Monitor blood pressure regularly, as bevacizumab can cause hypertension.
- Use with caution in patients with a history of bleeding disorders or recent surgeries.
- Not recommended during pregnancy or breastfeeding without consulting a healthcare provider.
Conclusion:
Bevacizumab (100 mg) is a targeted therapy used for various cancers, including colorectal, lung, breast, kidney, and ovarian cancers. Treatment regimens are tailored by healthcare professionals to optimize effectiveness and manage potential side effects.
Yes! I am InterestedRequest A Callback
Bevacizumab Injection (Bevacirel 400mg Injection)
Product Price: Rs 27,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 400 mg/16 ml |
| Brand | Bevacirel |
| Country of Origin | Made in India |
| Manufacturer | Reliance Life Sciences |
| Packaging Size | 1 Injection in 1 Vial |
| Treatment | Kidney cancer |
Bevacizumab, marketed as Bevacirel 400 mg, is a monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is used in the treatment of various cancers by inhibiting angiogenesis, the process by which tumors develop their own blood supply.
IndicationsBevacizumab is indicated for:
- Metastatic Colorectal Cancer: Often used in combination with chemotherapy.
- Non-Small Cell Lung Cancer (NSCLC): Indicated in combination with chemotherapy for advanced disease.
- Breast Cancer: Used in specific settings for HER2-negative cases.
- Renal Cell Carcinoma: Effective for advanced renal cancer.
- Cervical Cancer: Used in combination with other therapies.
Bevacizumab binds to VEGF, preventing it from interacting with its receptors on endothelial cells. This action inhibits the formation of new blood vessels, thereby restricting the tumor's growth and spread by cutting off its blood supply.
Dosage and Administration- Standard Dosage: The recommended dose of Bevacirel 400 mg is typically 5 mg/kg or 10 mg/kg, administered intravenously every two weeks or every three weeks, depending on the cancer type and treatment regimen.
- Administration: Given as an intravenous infusion. Initial doses should be administered slowly to monitor for infusion-related reactions.
Bevacizumab is contraindicated in:
- Hypersensitivity: Known allergy to bevacizumab or any components of the formulation.
- Recent Surgery or Wound Healing Issues: Should not be administered to patients with significant surgical wounds or bleeding.
- Hemorrhage Risk: Monitor for signs of serious bleeding, especially in patients with metastatic disease.
- Gastrointestinal Perforation: Assess patients for symptoms indicating gastrointestinal perforation, as this can be a serious complication.
- Hypertension: Monitor blood pressure; bevacizumab can cause or exacerbate hypertension.
Common side effects may include:
- Fatigue
- Nausea and vomiting
- Diarrhea
- Hypertension
- Headache
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Gastrointestinal perforation
- Arterial thromboembolic events (e.g., stroke, myocardial infarction)
- Hemorrhage (serious bleeding)
Bevacizumab may interact with other medications that affect blood pressure or coagulation. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Bevacizumab Injection (Bevacirel 400 mg) in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Keep out of reach of children.
Patient Counseling Information- Advise patients to report any signs of severe bleeding, gastrointestinal issues, or unusual symptoms.
- Discuss the importance of adhering to the treatment schedule and regular monitoring for blood pressure and other vital signs.
- Inform patients about potential side effects and when to seek medical attention.
Bevacizumab Injection (Bevacirel 400 mg) is a key therapeutic option in oncology, providing targeted treatment by inhibiting tumor blood vessel formation. Close monitoring and effective communication with healthcare providers are essential for managing side effects and optimizing treatment outcomes.
Yes! I am InterestedRequest A Callback
Bevacizumab Infusion (Versavo 400mg Solution For Infusion)
Product Price: Rs 23,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 400 mg/16 ml |
| Brand | Versavo |
| Manufacturer | Dr Reddy's Laboratories Ltd |
| Treatment | Cancer of colon and rectum |
| Packaging Size | 16 ml in 1 Vial |
Bevacizumab, marketed as Versavo 400 mg, is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is used in cancer treatment to prevent the growth of blood vessels that supply tumors.
IndicationsBevacizumab is indicated for:
- Metastatic Colorectal Cancer: Often combined with chemotherapy.
- Non-Small Cell Lung Cancer (NSCLC): Administered with chemotherapy for advanced stages.
- Breast Cancer: Used with other treatments for HER2-negative breast cancer.
- Renal Cell Carcinoma: Effective for advanced renal cell carcinoma.
- Glioblastoma: Used in patients with recurrent glioblastoma.
Bevacizumab binds to VEGF, blocking its interaction with VEGF receptors on endothelial cells. This inhibits angiogenesis, starving tumors of blood supply essential for growth.
Dosage and Administration- Standard Dosage: Typical dosing ranges from 5-15 mg/kg every 2 to 3 weeks.
- Administration: Given as an intravenous infusion. Monitor infusion rates, especially for the first dose.
Bevacizumab is contraindicated in:
- Hypersensitivity: Known allergy to bevacizumab.
- Severe Hemorrhage: Not recommended for patients with a recent history of significant bleeding.
- Gastrointestinal Perforations: Monitor for signs of perforation, especially in those with a history of diverticulitis.
- Wound Healing Complications: Use caution in patients undergoing surgery, as bevacizumab can impair healing.
- Hypertension: Regular blood pressure monitoring is essential.
Common side effects may include:
- Fatigue
- Nausea
- Diarrhea
- Hypertension
- Headache
Serious side effects can include:
- Severe allergic reactions
- Gastrointestinal perforation
- Wound healing complications
- Thromboembolic events
Bevacizumab may interact with medications affecting blood pressure or anticoagulants. Patients should inform healthcare providers about all medications.
Storage InstructionsStore Bevacizumab Infusion (Versavo 400 mg) in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
Patient Counseling Information- Advise patients to report unusual bleeding, signs of infection, or gastrointestinal symptoms.
- Discuss adherence to the treatment schedule and the importance of follow-up appointments.
- Inform patients about potential side effects and the need for blood pressure monitoring.
Bevacizumab Infusion (Versavo 400 mg) is crucial in managing various cancers, targeting tumor blood supply effectively. Ongoing monitoring and communication with healthcare providers are essential for managing side effects and optimizing treatment.
Yes! I am InterestedRequest A Callback
Genexol Pm Paclitaxel 100mg Injection
Product Price: Rs 14,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Packaging Type | Vial |
| Brand Name | Genexol-PM |
| Manufacturer | Lupin Ltd |
| Usages | Breast cancer,Non-small cell lung cancer,Pancreatic cancer |
Genexol PM is a formulation of Paclitaxel, a chemotherapy medication used in the treatment of various types of cancer. This injection is designed to provide a more efficient and effective delivery of the drug, enhancing its therapeutic benefits.
IndicationsGenexol PM is indicated for:
- Breast Cancer: Used in both early-stage and metastatic settings, often in combination with other chemotherapeutic agents.
- Non-Small Cell Lung Cancer (NSCLC): Administered for advanced NSCLC, typically after other treatments have failed.
- Ovarian Cancer: Effective in treating patients with recurrent or advanced ovarian cancer.
- Kaposi's Sarcoma: Used in patients with HIV-related Kaposi's sarcoma.
Paclitaxel works by stabilizing microtubules and preventing their disassembly, which inhibits cell division and leads to apoptosis in rapidly dividing cancer cells. This mechanism makes it effective against tumors that proliferate quickly.
Dosage and Administration- Standard Dosage: The typical dose of Genexol PM is 175 mg/m² administered as an intravenous infusion, often given every three weeks. However, specific regimens may vary based on cancer type and patient response.
- Administration: Administered via slow intravenous infusion over 3 hours. Pre-medication with corticosteroids and antihistamines may be required to reduce the risk of hypersensitivity reactions.
Genexol PM is contraindicated in:
- Hypersensitivity: Known allergy to paclitaxel or any formulation components.
- Severe Bone Marrow Suppression: Patients with significant neutropenia or thrombocytopenia.
- Myelosuppression: Regular monitoring of blood counts is essential due to the risk of neutropenia and increased infection risk.
- Cardiac Effects: Caution in patients with pre-existing cardiac conditions, as paclitaxel can cause arrhythmias.
- Infusion Reactions: Monitor patients closely for signs of infusion-related reactions, particularly during the first dose.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Hair loss
- Diarrhea
- Peripheral neuropathy
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Myelosuppression (severe neutropenia)
- Cardiac arrhythmias
- Infusion-related reactions
Paclitaxel may interact with other medications that are metabolized by liver enzymes, particularly those that can cause myelosuppression. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Genexol PM (Paclitaxel 100 mg Injection) at controlled room temperature, away from light. Protect from freezing and keep out of reach of children.
Patient Counseling Information- Advise patients to report any signs of infection, unusual bleeding, or severe gastrointestinal symptoms.
- Emphasize adherence to the treatment schedule and the importance of regular blood tests for monitoring.
- Inform patients about potential side effects and the importance of reporting them promptly.
Genexol PM (Paclitaxel 100 mg Injection) is a vital treatment option for various cancers, providing significant therapeutic benefits. Proper administration and monitoring are critical for maximizing treatment efficacy and minimizing risks.
Yes! I am InterestedRequest A Callback
Bortelive 2 Injection Bortezomib
Product Price: Rs 8,500 / PieceGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 2 mg |
| Form | Injection |
| Packaging Type | Vial |
| Storage Condition | Controlled room temperature 20 to 25 DegreeC ; excursions permitted from 15 DegreeC to 30 DegreeC |
| Brand Name | Bortrlive |
| Treatment | Cancer |
Bortelive 2 is an injectable formulation of Bortezomib, a proteasome inhibitor used in the treatment of certain types of cancer, primarily multiple myeloma and certain types of lymphoma. It works by interfering with the proteasome's function, leading to the accumulation of regulatory proteins that promote apoptosis (cell death) in cancer cells.
IndicationsBortelive 2 is indicated for:
- Multiple Myeloma: Treatment of patients who have received at least one prior therapy or as initial treatment.
- Mantle Cell Lymphoma: Used in patients who have received at least one prior therapy.
Bortezomib inhibits the proteasome, a cellular complex responsible for degrading ubiquitinated proteins. This inhibition leads to the accumulation of pro-apoptotic factors and inhibition of anti-apoptotic factors, thereby promoting cell death in malignant cells.
Dosage and Administration- Standard Dosage: The typical starting dose is 1.0 mg/m² administered as an intravenous injection or subcutaneously. Treatment is usually given in cycles, often twice a week for two weeks, followed by a week off.
- Administration: For intravenous use, it should be administered slowly over 3 to 5 seconds. If administered subcutaneously, it can be injected into the abdomen or thigh.
Bortelive 2 is contraindicated in:
- Hypersensitivity: Known allergy to bortezomib or any component of the formulation.
- Severe Thrombocytopenia: Patients with significantly low platelet counts should not receive this medication.
- Peripheral Neuropathy: Monitor for signs of peripheral neuropathy, as bortezomib can cause or exacerbate existing neuropathy.
- Myelosuppression: Regular blood count monitoring is essential due to the risk of thrombocytopenia, neutropenia, and anemia.
- Cardiac Events: Caution in patients with pre-existing cardiac conditions; monitor closely for signs of heart failure.
Common side effects may include:
- Nausea and vomiting
- Diarrhea
- Fatigue
- Peripheral neuropathy (tingling or numbness)
- Thrombocytopenia (low platelet count)
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiac complications (including heart failure)
- Tumor lysis syndrome (a potentially life-threatening condition due to rapid cell death)
Bortezomib may interact with other medications that affect blood cell counts or those that impact the liver's enzyme activity. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Bortelive 2 Injection in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Once reconstituted, it should be used promptly.
Patient Counseling Information- Educate patients on the potential side effects and the importance of reporting any unusual symptoms, such as numbness or weakness.
- Discuss the need for regular blood tests to monitor blood cell counts.
- Advise patients on the importance of adhering to the treatment schedule and attending follow-up appointments.
Bortelive 2 Injection is a valuable treatment option for multiple myeloma and mantle cell lymphoma, offering significant therapeutic benefits. Proper administration and monitoring are crucial for maximizing treatment efficacy and minimizing risks.
Yes! I am InterestedRequest A Callback
Nudoxa Doxorubicin 50mg/25ml injection
Product Price: Rs 9,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 50 mg |
| Pack Size | 25 ml |
| Pack Type | Vial |
| Brand Name | Nudoxa |
| Manufacturer | Zydus Cadila |
| Usages | Treatment of Breast Cancer |
Nudoxa is an injectable formulation of Doxorubicin, an anthracycline chemotherapy agent used in the treatment of various cancers. It works by interfering with the DNA replication process in cancer cells, ultimately leading to cell death.
IndicationsNudoxa is indicated for:
- Breast Cancer: Used in both early-stage and metastatic settings.
- Lymphomas: Effective in the treatment of Hodgkin's and non-Hodgkin's lymphoma.
- Leukemias: Used in some cases of acute myeloid leukemia (AML).
- Sarcomas: Treatment of soft tissue sarcomas.
- Ovarian Cancer: Often used in combination with other chemotherapeutic agents.
Doxorubicin binds to DNA and inhibits the action of topoisomerase II, an enzyme critical for DNA replication and repair. This action prevents cells from dividing and leads to apoptosis (programmed cell death), making it effective against rapidly dividing cancer cells.
Dosage and Administration- Standard Dosage: The dosage of Nudoxa is individualized based on the type of cancer, patient’s body surface area, and treatment regimen. A common starting dose is 60-75 mg/m² administered intravenously every 21 days.
- Administration: Administered via slow intravenous infusion over 15-30 minutes. Care must be taken to avoid extravasation, which can cause tissue damage.
Nudoxa is contraindicated in:
- Hypersensitivity: Known allergy to doxorubicin or any component of the formulation.
- Severe Cardiac Conditions: Patients with pre-existing heart disease or significant cardiac dysfunction.
- Pregnancy: Not recommended during pregnancy due to potential harm to the fetus.
- Cardiotoxicity: Regular monitoring of cardiac function is essential due to the risk of heart failure, especially with cumulative doses.
- Myelosuppression: Monitor blood counts regularly as doxorubicin can cause significant suppression of bone marrow function.
- Infection Risk: Increased susceptibility to infections due to leukopenia.
Common side effects may include:
- Nausea and vomiting
- Hair loss (alopecia)
- Mouth sores (mucositis)
- Fatigue
- Red discoloration of urine (due to excretion of doxorubicin)
Serious side effects can include:
- Cardiac toxicity (heart failure)
- Severe allergic reactions (anaphylaxis)
- Secondary malignancies (due to chemotherapy)
Doxorubicin may interact with other medications that affect cardiac function or have myelosuppressive effects. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Nudoxa (Doxorubicin 50 mg/25 ml Injection) at controlled room temperature, protected from light. Do not freeze.
Patient Counseling Information- Educate patients about recognizing side effects and when to seek medical attention.
- Discuss the importance of adhering to the treatment schedule and regular follow-up appointments.
- Advise patients to maintain good hydration and nutrition during treatment.
Nudoxa (Doxorubicin 50 mg/25 ml Injection) is a potent chemotherapy agent effective against various cancers. Proper administration and monitoring are critical for maximizing its therapeutic benefits while minimizing potential risks.
Yes! I am InterestedRequest A Callback
Doxorubicin Liposomal Injection (Pegadria 20mg Injection)
Product Price: Rs 1,700 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 2mg |
| Pack Type | Vial |
| Storage Condition | Store in a refrigerator (2 - 8 DegreeC). Do not freeze. |
| Brand Name | Pegadria |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Dosage Form | 20mg |
| Packaging Size | 1 Injection in 1 Vial |
Pegadria is an injectable formulation of Doxorubicin, a chemotherapy medication encapsulated in liposomes. This liposomal delivery system enhances the drug’s efficacy and reduces its toxicity, particularly the cardiotoxic effects typically associated with conventional doxorubicin.
IndicationsPegadria is indicated for:
- Breast Cancer: Treatment of metastatic breast cancer, often used in combination with other therapies.
- Ovarian Cancer: Used in patients with ovarian cancer who have received prior chemotherapy.
- Multiple Myeloma: Used as part of combination therapy for patients with relapsed or refractory multiple myeloma.
Doxorubicin exerts its antitumor effects by intercalating into DNA, inhibiting topoisomerase II, and disrupting DNA replication and transcription. The liposomal formulation allows for targeted delivery to tumors while minimizing systemic exposure, thus reducing side effects.
Dosage and Administration- Standard Dosage: The typical starting dose of Pegadria is 40 mg/m² administered as an intravenous infusion every 4 weeks. Dosage may vary based on individual patient factors and response.
- Administration: Administer via slow intravenous infusion over 60 minutes. Avoid extravasation during administration, as it can lead to tissue damage.
Pegadria is contraindicated in:
- Hypersensitivity: Known allergy to doxorubicin or any component of the liposomal formulation.
- Severe Cardiac Disease: Patients with significant cardiac impairment or heart failure.
- Cardiotoxicity: Monitor cardiac function regularly, particularly in patients with pre-existing heart conditions or those receiving other cardiotoxic drugs.
- Myelosuppression: Regular blood count monitoring is essential due to the risk of neutropenia and thrombocytopenia.
- Infusion Reactions: Observe patients for infusion-related reactions, which may include fever, chills, or rash.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Constipation
- Mouth sores (mucositis)
- Hair loss (alopecia)
Serious side effects can include:
- Heart failure or other cardiac complications
- Severe allergic reactions (anaphylaxis)
- Secondary malignancies (due to chemotherapy)
Pegadria may interact with other medications that affect heart function or blood counts. Patients should inform their healthcare provider about all medications, including over-the-counter drugs and supplements.
Storage InstructionsStore Pegadria (Doxorubicin Liposomal Injection 20 mg) in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
Patient Counseling Information- Educate patients on recognizing the signs of side effects and the importance of reporting them promptly.
- Discuss the importance of adhering to the treatment schedule and attending regular follow-up appointments.
- Advise patients to maintain hydration and a balanced diet during treatment.
Pegadria (Doxorubicin Liposomal Injection 20 mg) represents a significant advancement in the treatment of various cancers, providing effective chemotherapy with reduced toxicity. Proper administration and monitoring are essential for achieving the best possible outcomes.
Yes! I am InterestedRequest A Callback
View More